Mucopolysaccharidosis (MPS) Treatment Market Size & Share, by Type (Hurler syndrome, Hunter syndrome), End-user (Hospitals, Pharmaceuticals, Research Institutions) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

Growth Drivers

• Advancements in Enzyme Replacement Therapy (ERT): Enzyme Replacement Therapy (ERT) stands as a cornerstone in the network management solutions of MPS, offering targeted intervention by providing the deficient enzymes responsible for GAG metabolism. The sector has experienced substantial growth, with research continually refining the efficacy and delivery methods of ERT. According to a study, ERT has demonstrated considerable improvements in clinical outcomes, with patients experiencing enhanced pulmonary function and reduction in hepatosplenomegaly.
• Increased Awareness and Early Diagnosis: The growing awareness about MPS among healthcare professionals, caregivers, and the general public has led to early diagnosis and intervention, a critical factor in improving patient outcomes. Timely diagnosis empowers healthcare providers to initiate treatments during the earlier stages of the disease.
• Emergence of Novel Therapies: The MPS treatment landscape has expanded beyond traditional approaches, with the emergence of novel therapies like gene therapy and substrate reduction therapy. These innovative modalities hold promise in addressing the genetic basis of MPS and minimizing GAG accumulation.

Challenges

• Limited Awareness and Early Diagnosis: Despite efforts to raise awareness, many cases of MPS still go undiagnosed or are diagnosed at a later stage. This delay in diagnosis can impede the effectiveness of treatments, as interventions are often most impactful when initiated early in the disease course.
• Complexity of Disease Subtypes
• Access to Specialized Care